When: Post-FDA pullback to $135-140 zone

Then: Reserve balance deployment

HOLD; 3-4% position sizing; 129.50 stop; wait for 135-140 entry zone

• Golden cross at 132 already played out—buying at 148.77 with limited upside and full prior rally as downside risk
• RSI at 69.97 with price at upper Bollinger Band (150.14) indicates momentum exhaustion and elevated pullback probability
• Volume declining to 4.57M on August 25 from 6.7M prior—lowest of entire rally—signals weak breakout conviction, not healthy consolidation
• Stock rallied 13.4% in 16 sessions to swing high of 148.93 approaching major resistance with insufficient demand
• FDA catalyst on August 27 is binary event risk—negative outcome could cause 10-15% gap down regardless of 9.5B FCF floor
• Macro backdrop unfavorable: 86% odds of no Fed cuts in 2026, 32% September hike probability, restrictive policy compressing biotech multiples
• ATR of 3.88 supports conservative 3-4% sizing—tight 143.50 stop is unrealistic given gap-down risk on binary catalyst
• 50/200 SMA at 132 forms major confluence support zone; pullbacks of 10-15% in strong trends are normal and expected
• TTM net income anomaly of negative 3.24B reflects recurring write-down pattern that erodes investor confidence over time
• Wait zone of 135-140 provides 3-5% cushion below current levels and aligns with structural support—1-3 week wait maximum

→ vs aggressive: Golden cross at 132 is not a new entry signal; by the time 50 SMA crosses 200 SMA, the stock has already rallied substantially from that level—buying at 148.77 means chasing a move that has largely played out

→ vs aggressive: RSI 69.97 technically not overbought but practically misleading—parked at upper Bollinger Band immediately ahead of binary FDA catalyst with elevated probability of RSI rollover in next 5-10 sessions

→ vs aggressive: MACD at 4.17 and expanding histogram signals accelerating momentum but also mean reversion risk when this extended—easy money already made on this move

→ vs aggressive: Declining volume on August 25 close is not healthy consolidation—it is distribution pattern where original buyers step aside without fresh demand stepping in to push through 150.14 resistance

→ vs aggressive: Fundamentals provide eventual floor but path to floor can be very ugly—9.5B FCF and 15x earnings do not prevent 10-15% gap down on FDA setback

→ vs aggressive: Assumes friendly multiple backdrop and favorable catalyst outcome simultaneously—low-probability combination given restrictive macro environment

→ vs aggressive: 5-6% position sizing with 143.50 stop is inadequate—tight stop gets blown through on gap-down FDA event; must size for gap scenario, not orderly pullback

→ vs aggressive: 6.5/10 mildly bullish sentiment with medium confidence is not under-rating upside—bearish headlines on 11B R&D charge, GAAP loss, and HIV concentration are recurring concerns across multiple outlets

→ vs aggressive: Negative 3.24B TTM net income is not just non-cash noise—it represents recurring write-down pattern flagged as most significant red flag in fundamentals report

HOLD

• Golden cross is structurally bullish but lagging by design — current price 148.77 means substantial move already captured
• RSI 69.97 is one cent from overbought threshold at resistance with declining volume and binary FDA catalyst 2 days away — risk-adjusted response should be same as overbought
• Low volume at 148.77 intraday high is signature of distribution, not consolidation — buyers who started the move taking profits, insufficient new institutional demand
• Aggressive Analyst's survivorship bias: names where patience destroyed returns are forgotten because they went to zero
• Aggressive Analyst's position sizing math flawed: ATR 3.88 with stop at 143.50 (4% below price) ignores overnight gap risk on binary event — realized loss exceeds modeled 3.4%
• Conservative Analyst anchoring on worst-case 22% Feb-June drawdown which occurred during sector stress, not representative of normal GILD behavior
• Conservative Analyst conflating existing holders (cost basis 130) versus new entrants — differentiated approach warranted
• Fed policy assumption not data-supported: biotech currently outperforming due to FDA approval momentum and sector rotation, less rate-sensitive than growth tech
• Conservative Analyst underweighting constructive flow: Trodelvy EU approval, Nucleai AI partnership, Yeztugo ramp, raised guidance represent independent positives
• Bearish headline count (3 pieces on 11B R&D charge) represents same Q2 earnings data recycled, not independent concerns
• Recommendation: Existing holders hold with stop at 135 (50/200 SMA confluence), tighter than 129.50 stop which overstates gap risk
• New entrants: half position now at 148.77 with tight 143 stop, half reserved for breakout above 150 with volume above 5M or pullback to 135-140 with reversal candle
• Position sizing: 3-4% for now with tactical add to 5% post-FDA if favorable outcome, respecting binary risk without permanently capping exposure to confirmed uptrend in high-quality name

→ vs aggressive: Position sizing math wrong — ATR-based allocation with tight 143.50 stop ignores overnight gap risk on binary FDA event, producing realized losses far larger than modeled 3.4% per share

→ vs aggressive: Survivorship bias on 'patience destroys returns' — names where this happened are forgotten because they went to zero, while names preserving capital through binaries compounded

→ vs aggressive: Volume at resistance is distribution signature (low volume on up-day to 148.93 high), not consolidation — Aggressive Analyst's 'patient institutional buyers absorbing supply' characterization is confirmation bias

→ vs aggressive: Overstating remaining upside at 148.77 — golden cross is lagging, easy premium already captured, asymmetric risk described is not as clean as presented

→ vs conservative: Anchoring on worst-case 22% Feb-June drawdown from sector stress, not representative of normal GILD behavior — strong trends with fresh crosses often produce shallow 5-7% pullbacks to 143-146 before resuming

→ vs conservative: Conflating existing holders (cost basis 130) versus new entrants — differentiated sizing warranted, not uniform 3-4% cap across both groups

→ vs conservative: Fed policy assumption not data-supported — biotech currently outperforming due to FDA momentum and sector rotation, less rate-sensitive than growth tech

→ vs conservative: Constructive news flow underweighted: Trodelvy EU approval, Nucleai AI partnership, Yeztugo ramp, raised guidance are independent positives being dismissed in favor of recycled bearish headlines on accounting items